<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Axogen Inc — News on 6ix</title>
<link>https://6ix.com/company/axogen-inc</link>
<description>Latest news and press releases for Axogen Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/axogen-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354a6c78dffbe2df0e4ab2.webp</url>
<title>Axogen Inc</title>
<link>https://6ix.com/company/axogen-inc</link>
</image>
<item>
<title>Axogen, Inc. Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-reports-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>Raises Full Year Revenue Guidance to at Least 20% Growth or $270 millionALACHUA, Fla. and TAMPA, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter Financial Results First quarter 2026 revenue was $61.5 million, a 26.6% increase compared to f</description>
</item>
<item>
<title>CVRx Announces Nomination of Michael Dale for Election to the Board of Directors</title>
<link>https://6ix.com/company/axogen-inc/news/cvrx-announces-nomination-of-michael-dale-for-election-to-the-board-of-directors-13</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/cvrx-announces-nomination-of-michael-dale-for-election-to-the-board-of-directors-13</guid>
<pubDate>Mon, 20 Apr 2026 20:30:00 GMT</pubDate>
<description>MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026. "Michael has achieved an outstanding record of commercial success in the medical</description>
</item>
<item>
<title>Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-to-report-first-quarter-2026-financial-results-on-april-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-to-report-first-quarter-2026-financial-results-on-april-28-2026</guid>
<pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the first quarter of 2026 on Tuesday, April 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conf</description>
</item>
<item>
<title>Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-report-fourth-quarter-120000994</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-report-fourth-quarter-120000994</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participati</description>
</item>
<item>
<title>Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-announces-pricing-upsized-124-041800940</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-announces-pricing-upsized-124-041800940</guid>
<pubDate>Thu, 22 Jan 2026 04:18:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen</description>
</item>
<item>
<title>Axogen Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-announces-proposed-public-offering-210900705</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-announces-proposed-public-offering-210900705</guid>
<pubDate>Wed, 21 Jan 2026 21:09:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $</description>
</item>
<item>
<title>Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-reports-preliminary-unaudited-revenue-fourth-quarter-and-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-reports-preliminary-unaudited-revenue-fourth-quarter-and-full-year-2025</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-participate-jp-morgan-2026-healthcare-conference-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-participate-jp-morgan-2026-healthcare-conference-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-announces-fda-approval-biologics-license-application-avancer-acellular-nerve</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-announces-fda-approval-biologics-license-application-avancer-acellular-nerve</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-participate-multiple-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-participate-multiple-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen, Inc. Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-reports-third-quarter-2025-financial-results-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-reports-third-quarter-2025-financial-results-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc.</description>
</item>
<item>
<title>Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-report-2025-third-quarter-financial-results-october-29-2025-2025-10-15</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-report-2025-third-quarter-financial-results-october-29-2025-2025-10-15</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-provides-update-fda-review-timeline-avance-nerve-graft-2025-08-25</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-provides-update-fda-review-timeline-avance-nerve-graft-2025-08-25</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>FDA PDUFA goal date extended by three months ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that</description>
</item>
<item>
<title>Axogen, Inc. Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-reports-second-quarter-110000425</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-reports-second-quarter-110000425</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>Raises Full Year Revenue Guidance to at Least 17% Growth or $219 MillionALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the</description>
</item>
<item>
<title>Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-participate-canaccord-genuity-45th-annual-growth-conference-2025-07-29</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-participate-canaccord-genuity-45th-annual-growth-conference-2025-07-29</guid>
<pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-report-2025-second-quarter-financial-results-august-5-2025-2025-07-22</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-report-2025-second-quarter-financial-results-august-5-2025-2025-07-22</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-participate-goldman-sachs-global-healthcare-conference-2025-05-28</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-participate-goldman-sachs-global-healthcare-conference-2025-05-28</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen, Inc. Reports 2025 First Quarter Financial Results</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-inc-reports-2025-first-quarter-financial-results-2025-05-08</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-inc-reports-2025-first-quarter-financial-results-2025-05-08</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical</description>
</item>
<item>
<title>Axogen Announces Chief Financial Officer Transition</title>
<link>https://6ix.com/company/axogen-inc/news/axogen-announces-chief-financial-officer-transition-2025-05-08</link>
<guid isPermaLink="true">https://6ix.com/company/axogen-inc/news/axogen-announces-chief-financial-officer-transition-2025-05-08</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>Lindsey Hartley, CPA, appointed as Chief Financial Officer to succeed Nir Naor ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc.</description>
</item>
</channel>
</rss>